A Phase 3, Open-label, Long-term Safety Study of Oral Linaclotide Administered to Pediatric Participants With Functional Constipation (FC) or Irritable Bowel Syndrome With Constipation (IBS-C)
Latest Information Update: 25 Jun 2025
At a glance
- Drugs Linaclotide (Primary)
- Indications Irritable bowel syndrome
- Focus Adverse reactions
- Sponsors AbbVie; Allergan
Most Recent Events
- 18 Jun 2025 Status changed from active, no longer recruiting to completed.
- 22 Apr 2025 According to an Ironwood Pharmaceuticals media release, the data from this trial will be presented at the 2025 Digestive Disease Week (DDW) meeting, taking place May 3-6 in San Diego, CA.
- 12 Sep 2024 This trial has been completed in Hungary , according to European Clinical Trials Database record.